Novel high-sensitivity liquid biopsy in cancer therapy
The analysis of cancer biomarkers during the follow-up of the treatment and in the postoperative period requires high sensitivity. The EU-funded BiopSense project is developing a novel technology that allows very sensitive detection of single-nucleotide polymorphism in the samples, enabling point-of-care screening of liquid biopsies. This diagnostics platform will represent an open system that can accommodate the design of new diagnostic targets. The technology is based on a patented invention and will include features for automated sample preparation and lab-on-chip design. The project objectives include verification of the complete platform components and establishment of the sensitivity and accuracy of the chemistry for evaluation against a competitive mass spectrometry platform.
Fields of science
Funding SchemeERC-POC - Proof of Concept Grant
See on map